Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents
Vascular Medicine
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Büller, H. R
Right arrow Articles by Koopman, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Büller, H. R
Right arrow Articles by Koopman, M. M.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Blood Thinners
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Early discharge strategies following venous thrombosis

Harry R Büller

Centre for Thrombosis, Haemostasis, Atherosclerosis and Inflammation Research, Academic Medical Centre, University of Amsterdam, The Netherlands

Roderik A Kraaijenhagen

Centre for Thrombosis, Haemostasis, Atherosclerosis and Inflammation Research, Academic Medical Centre, University of Amsterdam, The Netherlands

Maria MW Koopman

Centre for Thrombosis, Haemostasis, Atherosclerosis and Inflammation Research, Academic Medical Centre, University of Amsterdam, The Netherlands

Low-molecular-weight heparin therapy is administered subcutaneously, not intravenously. This has made possible the management of selected patients who have acute deep venous thrombosis as outpatients. Others can be treated with an abbreviated several day hospitalization rather than the conventional 5 or more hospital days needed for administration of continuous intravenous unfractionated heparin. Two large studies, Tasman and a Canadian trial, have demonstrated the efficacy and safety of low-molecular-weight heparin in this setting. Now, the task is to develop guidelines for widespread application of these findings to daily clinical practice. However, successful home treatment will require intensive patient education as well as an extensive infrastructure of supportive nursing and physician services. Careful patient follow-up will be crucially important.

Key Words: anticoagulation • deep venous thrombosis • low-molecular-weight heparin • out-patient therapy • pulmonary embolism • venous thromboembolism

Vascular Medicine, Vol. 3, No. 1, 47-50 (1998)
DOI: 10.1177/1358836X9800300110
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?